Summary & Overview
CPT 81510: Prenatal Triple-Analyte Algorithmic Risk Assessment
CPT code 81510 denotes a laboratory-based algorithmic risk assessment that combines measured levels of AFP, uE3, and hCG with patient data to produce a reported patient risk score. This test is used in prenatal screening contexts to estimate risk for certain fetal conditions and is notable nationally for its role in noninvasive risk stratification that can influence downstream diagnostic and counseling decisions. Key payers in national coverage discussions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the service definition, common payer coverage considerations, and clinical context for use. The publication outlines typical sites of service, common modifiers in billing practice, and operational implications for laboratories performing combined analyte measurement with algorithmic interpretation. It also highlights benchmarking and reimbursement themes relevant to labs and payers, policy updates affecting algorithm-based laboratory tests, and clinical considerations around prenatal screening workflows. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 81510 describes a laboratory service in which the lab analyst performs technical testing for three analytes — alpha-fetoprotein (AFP), unconjugated estriol (uE3), and human chorionic gonadotropin (hCG) — and applies an algorithmic analysis using patient data and the test results to generate and report a patient risk score. The service type is a laboratory-based algorithmic risk assessment. The typical site of service is a clinical laboratory or centralized diagnostic testing facility, where specimen processing, immunoassays or equivalent analyte testing, and algorithmic computation are performed.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves a pregnant patient undergoing second‑trimester aneuploidy risk assessment. The ordering obstetric provider (obstetrician-gynecologist or maternal-fetal medicine specialist) collects a maternal serum sample and submits clinical data (maternal age, gestational age, weight, diabetes status, race/ethnicity, and prior obstetric history) with the specimen. The laboratory performs quantitative immunoassays for alpha-fetoprotein (AFP), unconjugated estriol (uE3), and human chorionic gonadotropin (hCG), and then runs a validated algorithm that integrates the three analyte values with the patient data to generate a computed patient risk score for neural tube defects and chromosomal abnormalities (e.g., trisomy 21, trisomy 18). The lab analyst documents the technical testing, performs quality control, and reports the risk score and interpretation to the ordering provider via the laboratory information system. Typical site of service is an outpatient clinical laboratory or hospital clinical laboratory with specimen collection in an outpatient clinic, prenatal clinic, or physician office collection area. The service type is a laboratory algorithmic risk assessment based on assay results and patient data, representing the technical component of a multi-analyte biochemical screening test.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Service not otherwise classified (placeholder) | Rarely used; billers may use as payer-specific placeholder when no other modifier applies per payer guidance |